Skip to content
Frovatriptan
Frova (frovatriptan) is a small molecule pharmaceutical. Frovatriptan was first approved as Frova on 2001-11-08. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D and 5-hydroxytryptamine receptor 1B. In addition, it is known to target 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Frova (generic drugs available since 2016-03-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Frovatriptan succinate
Tradename
Company
Number
Date
Products
FROVAEndoN-021006 RX2001-11-08
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
frovatriptanANDA2022-12-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
migraine disordersEFO_0003821D008881G43
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02C: Antimigraine preparations
— N02CC: Selective serotonin (5ht1) agonists
— N02CC07: Frovatriptan
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G43——4127
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Secondary headache disordersD051271—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
General anesthesiaD000768————11
HemorrhageD006470MP_0001914R58————11
MetrorrhagiaD008796HP_0100608N92.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFROVATRIPTAN
INNfrovatriptan
Description
Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.
Classification
Small molecule
Drug classantimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1
Identifiers
PDB—
CAS-ID158747-02-5
RxCUI228783
ChEMBL IDCHEMBL1279
ChEBI ID—
PubChem CID77992
DrugBankDB00998
UNII IDH82Q2D5WA7 (ChemIDplus, GSRS)
Target
Agency Approved
HTR1D
HTR1D
HTR1B
HTR1B
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
3352
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
P28221
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Alternate
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
3350
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Q6LAE7
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 258 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16 adverse events reported
View more details